As pSivida gears up to begin distribution of its Illuvien eye treatment in Europe, it plans to re-submit its new drug application to the FDA for the drug/device combination. It's been a rocky road for pSivida's (NSDQ:PSDV) Illuvien, a drug/device combination for macular degeneration, but the company hopes that new trial data will pave the way to regulatory approval in the U.S.
